Tag: long term outcomes

Claims That Long-term Antipsychotic Use Leads to Better Outcomes are Misleading,...

9
Researchers reveal the limitations and misleading interpretations of two recent studies that claim to demonstrate that long-term antipsychotic use leads to better outcomes.

Antidepressant Use Leads to Worse Long Term Outcomes, Study Finds

32
Results from a 30-year prospective study demonstrated worse outcomes for people who took antidepressants, even after controlling for gender, education level, marriage, baseline severity, other affective disorders, suicidality, and family history of depression.

Rigorous Study Finds Antidepressants Worsen Long-Term Outcomes

37
A new study conducted by Jeffrey Vittengl at Truman University has found that taking antidepressant medications resulted in more severe depression symptoms after nine years.

SAMHSA’s Rose-Colored Lens

59
SAMHSA should be commended for undertaking an important educational task with laudable goals. Unfortunately, I have to conclude that SAMHSA’s Recovery to Practice module on medications for psychiatrists is a very minimal and even misleading attempt at educating psychiatrists.

Study Suggests Long-Term Antipsychotic Use May Result in Poorer Cognitive Functioning

11
Association found between long-term antipsychotic use and poorer performance on cognitive tasks in adults diagnosed with ‘schizophrenia.’

The Case Against Antipsychotics

130
This review of the scientific literature, stretching across six decades, makes the case that antipsychotics, over the long-term, do more harm than good. The drugs lower recovery rates and worsen functional outcomes over longer periods of time.

Tapering Off Medications When “Symptoms Have Remitted”: Does That Make Sense?

2
While a 2-year outcome study by Wunderink, et al. has been cited as evidence that guided discontinuation of antipsychotics for people whose psychosis has remitted results in twice as much “relapse,” a not-yet-published followup of that study, extending it to 7 years using a naturalistic followup, finds that the guided discontinuation group had twice the recovery rates, and no greater overall relapse rate (with a trend toward the medication group having more relapse.)